Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Bullboard - Stock Discussion Forum BioVaxys Technology Corp. C.BIOV

Alternate Symbol(s):  BVAXF

BioVaxys Technology Corp. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on improving patient lives with novel immunotherapies based on the DPX immune-educating technology platform and its HapTenix neoantigen tumor cell construct platform, for treating cancers, infectious disease, antigen desensitization and other immunological fields. The Company's clinical... see more

CSE:BIOV - Post Discussion

BioVaxys Technology Corp. > 1 million shares CDN traded /OTC $US traded 1/2 mil
View:
Post by frankman on Nov 26, 2024 2:21pm

1 million shares CDN traded /OTC $US traded 1/2 mil

Sym-X Bid - Ask Last Chg %Ch Vol $Vol #Tr
    ATS 217.0 0.06 · 0.065 46.0 0.065     1,126.1 66 95
CSE - C 217.0 0.06 · 0.065 46.0 0.06 -0.005 -7.7 643.4 38 40
NEO ATS - U   0.065     50.0 3 5
Omega - O   0.065     369.0 22 33
CX2 - H   0.06 -0.005 -7.7 58.9 3 9
CXD - D   0.0625 -0.0025 -3.8 2.9 0 2
TriAct - M   0.065     1.9   6
Be the first to comment on this post
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities